8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
Apr 27, 2026·SEC
Xencor, Inc.(XNCR)Earnings, Financials & Key Ratios
XNCR•NASDAQ
$14.89
Price updated Jul 6, 2026
AboutXencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.Show more
- Revenue$126M+13.7%
- EBITDA-$167M-0.4%
- Net Income-$92M+60.5%
- EPS (Diluted)-1.24+65.4%
- Gross Margin91.63%-8.4%
- EBITDA Margin-132.98%+11.6%
- Operating Margin-141.35%+12.5%
- Net Margin-73.2%+65.2%
- ROE-14.04%+59.5%
XNCR Price & Volume
Xencor, Inc. (XNCR) stock price & volume — 10-year historical chart
Loading chart...
Erratic Milestone Revenue Masks Deep Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Critical Cash Runway Depletion
Key Thesis Takeaways
- Xencor's reliance on unpredictable milestone-based revenue, which saw a 59.7% contraction in 2025Q4, creates significant volatility that complicates long-term financial forecasting.
- While the company maintains high gross margins often exceeding 90%, these are consistently neutralized by heavy R&D expenditures that frequently exceed $50 million per quarter.
- Investors should monitor the critical depletion of cash reserves, which fell to $14.2 million in 2026Q1, as the firm's structural reliance on external financing to fund its clinical pipeline remains a primary risk factor.
Verdict Logic
the company's cash position has reached a critical low of $14.2 million as of 2026Q1, suggesting an urgent need for dilutive financing to sustain its ongoing R&D-heavy clinical operations.
XNCR Growth Metrics
Xencor, Inc. (XNCR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years16.29%
5 Years0.47%
3 Years-8.62%
TTM-32.48%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM19.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM27.76%
Return on Capital
10 Years-10.07%
5 Years-12.48%
3 Years-19.41%
Last Year-21.59%
XNCR Recent Earnings
Xencor, Inc. (XNCR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$1.71-163.1%
$0.65
Rev
$5M-83.8%
$28M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.09+85.9%
$0.64
Rev
$28M-5.8%
$30M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.08+88.9%
$0.72
Rev
$21M-29.9%
$30M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.41+47.4%
$0.78
Rev
$44M+78.9%
$24M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $1.71vs $0.65-163.1% | $5Mvs $28M-83.8% |
| Q1 2026 | Feb 25, 2026 | $0.09vs $0.64+85.9% | $28Mvs $30M-5.8% |
| Q4 2025 | Nov 5, 2025 | $0.08vs $0.72+88.9% | $21Mvs $30M-29.9% |
| Q3 2025 | Aug 6, 2025 | $0.41vs $0.78+47.4% | $44Mvs $24M+78.9% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Xencor, Inc. (XNCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.89 | $1.09B | -12.01 | 13.65% | -73.2% | -14.04% | — | |
| $29.98 | $3.02B | -9.11 | -4.26% | -156.36% | -68.97% | — | |
| $4.57 | $290.48M | -3.87 | 0.78% | -44.79% | -147.8% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $55.14 | $9.19B | 38.56 | -5.25% | 9.78% | 8.82% | — | |
| $25.33 | $1.86B | -23.45 | 38.87% | -126.33% | -0.25% | — |
Compare XNCR vs Peers
Xencor, Inc. (XNCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XNCR SEC Filings & Documents
Xencor, Inc. (XNCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when XNCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XNCR Frequently Asked Questions
Xencor, Inc. (XNCR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Xencor, Inc.'s revenue?
Xencor, Inc. (XNCR) reported $92.8M in revenue for fiscal year 2025. This represents a 1256% increase from $6.8M in 2011.
How fast is Xencor, Inc. growing?
Xencor, Inc. (XNCR) grew revenue by 13.7% over the past year. This is steady growth.
Is XNCR profitable?
Xencor, Inc. (XNCR) reported a net loss of $172.4M for fiscal year 2025.
Dividend & Returns
What is XNCR's return on equity?
Xencor, Inc. (XNCR) has a return on equity (ROE) of -14.0%. Negative ROE indicates the company is unprofitable.
What is Xencor, Inc.'s free cash flow?
Xencor, Inc. (XNCR) had negative free cash flow of $188.8M in fiscal year 2025, likely due to heavy capital investments.